FluoroPharma Medical, Inc.
FluoroPharma Medical, Inc.
Your view on FPMI
Overview
What the company does, where it operates, and who runs it.
About FluoroPharma Medical, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Edward L. Lyons Jr.
- Headquarters
- 8 Hillside Avenue, Montclair, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Edward L. Lyons Jr.
- Headquarters
- 8 Hillside Avenue, Montclair, NJ, US
FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States.
Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD.
The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for FluoroPharma Medical, Inc., and the rating behind it. FPMI last traded at $0.0002; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for FluoroPharma Medical, Inc.. Starting points for FluoroPharma Medical, Inc.: EPS -$0.06, beta -69.72 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for FluoroPharma Medical, Inc.. FluoroPharma Medical, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for FluoroPharma Medical, Inc.. Trailing twelve-month EPS for FluoroPharma Medical, Inc. stands at -$0.06. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for FluoroPharma Medical, Inc.. FluoroPharma Medical, Inc. has reported as a listed company since 2011. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
FluoroPharma Medical, Inc. valued side by side against its closest peers. FluoroPharma Medical, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold FluoroPharma Medical, Inc., and how their positions are changing. At a $6,852 market value, institutional positions materially move FluoroPharma Medical, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by FluoroPharma Medical, Inc. executives and directors. Shares of FluoroPharma Medical, Inc. have traded between $0.0001 and $0.0002 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming FluoroPharma Medical, Inc.. FluoroPharma Medical, Inc. is a $6,852 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming FluoroPharma Medical, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for FluoroPharma Medical, Inc.. Coverage tracks FluoroPharma Medical, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.